Pet CD20 Therapeutic Antibody Development

Creative Biolabs is dedicated to advancing the field of veterinary biotherapeutics by developing next-generation antibody therapeutics targeting key immune regulators in dogs and cats. Among these, CD20 has emerged as a particularly promising target for treating B-cell-related disorders in companion animals. Our specialized Pet CD20 Therapeutic Antibody Development service combines molecular immunology expertise, advanced discovery technologies, and species-adapted engineering to help veterinary pharmaceutical partners bring precision immunotherapies to market. If your R&D team is seeking a reliable partner for canine or feline CD20-targeted antibody discovery, we invite you to connect with us to discuss customized solutions.

Platforms in Therapeutic Antibody Discovery

Creative Biolabs provides a full range of discovery and optimization platforms designed to help therapeutic antibodies research and development.

• Phage Display: Using proprietary canine and feline antibody libraries, our phage display platform enables the identification of high-affinity binders against CD20 with excellent sequence diversity. This approach is ideal for generating fully species-compatible antibodies that minimize immunogenic risk.
• Single-B Cell Sorting: Our single-B cell sorting platform isolates antigen-specific B cells from immunized murine models, yielding naturally derived monoclonal antibodies. These antibodies serve as valuable precursors for engineering and species adaptation to canine or feline systems.
• Hybridoma Technology: We maintain robust hybridoma pipelines capable of producing murine anti-CD20 monoclonal antibodies, which can subsequently undergo molecular reformatting and optimization for use in pet species. This combination of classical and modern methods ensures efficiency and flexibility in antibody discovery.

Comprehensive Antibody Development Services

Our integrated development framework ensures that each CD20 therapeutic antibody is rigorously evaluated and optimized for safety, efficacy, and manufacturability in veterinary applications.

Antibody Characterization

We perform detailed kinetic, binding, and cross-reactivity assessments to confirm target specificity and functional potency.

Antibody Engineering

Our expertise includes Fc optimization, canine/feline isotype conversion, and affinity maturation to enhance pharmacological performance while reducing immune responses.

Preclinical Evaluation

Creative Biolabs provides comprehensive preclinical testing, including B-cell depletion assays, flow cytometry analyses, and safety evaluations in relevant veterinary models.

Antibody Development

From lead optimization to scalable expression and purification, our end-to-end development solutions ensure smooth progression toward future studies.

Discover How We Can Help - Request a Consultation

Why Focus on CD20?

CD20 is a transmembrane protein expressed primarily on the surface of B lymphocytes, playing a critical role in B-cell activation and differentiation. In companion animals, aberrant B-cell proliferation and survival contribute to various lymphoproliferative and autoimmune diseases. In dogs, CD20 is a key therapeutic target for B-cell lymphomas, one of the most common hematologic malignancies in the species. Cats, while less frequently affected, can also develop B-cell–driven lymphomas and immune-mediated disorders where CD20 modulation offers potential therapeutic benefit. Targeting CD20 provides a mechanism to selectively deplete pathological B cells while sparing other immune populations, offering a powerful treatment option for chronic or refractory diseases.

Mechanism of Action

Anti-CD20 therapeutic antibodies bind specifically to the extracellular domain of the CD20 molecule on mature B cells. This interaction triggers multiple immune-mediated mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct induction of apoptosis. Through these combined effects, anti-CD20 antibodies lead to targeted B-cell depletion, effectively suppressing overactive or malignant B-cell populations. In pets, this approach can help control diseases such as B-cell lymphoma, immune-mediated hemolytic anemia, and chronic autoimmune inflammation, while allowing normal immune reconstitution over time.

Fig 1. The defucosylated chimeric antibody depletes B cells in healthy beagle dogs.¹

Our Advantages

• Creative Biolabs stands apart through its veterinary-focused R&D ecosystem, integrating molecular biology, protein engineering, and preclinical expertise.
• Our species-specific antibody libraries and engineering workflows are tailored for the unique immunological environments of dogs and cats, ensuring optimal compatibility and safety.
• We emphasize collaborative development, offering flexible project models that align with your therapeutic pipeline goals.

Partner with Creative Biolabs

As veterinary immunotherapy continues to evolve, targeting CD20 represents one of the most impactful strategies in companion animal oncology and immune regulation. Creative Biolabs offers the scientific infrastructure, technical depth, and project management expertise to accelerate your program from concept to validated candidate.

Contact us today to discuss your Pet CD20 Therapeutic Antibody Development goals and explore how Creative Biolabs can support your research and product pipeline.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Mizuno, Takuya, et al. "Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment." Scientific reports 10.1 (2020): 11476. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41598-020-68470-9